In an era of health reform, diagnostic technologies that focus on prevention and test the viability of expensive treatment options are becoming increasingly valuable to health providers, payers, and patients. Historically, investment in this sector has not seen the vigor demonstrated with medical devices or biotech innovations. However, in today’s environment, diagnostics are becoming attractive opportunities for companies looking for collaborations or acquisitions as well as investors looking for cutting-edge technologies, all creating a robust industry on the brink of breaking through to the mainstream.
In this presentation, panelists will:
- Provide insight on the diagnostic industry on a local and national level
- Discuss key elements that are reviewed when assessing start-up opportunities
- Discuss where opportunities exist for maximizing profits
- Provide new strategies for raising funds in this dynamic marketplace
Panelist:
Ronald S. Eppen, Partner, Foley & Lardner LLP
Lucy Lu, Vice President of Business Development, Crescendo Bioscience
Natasha Paul, Ph.D., Scientific Investigator, TriLink Biotechnologies, Inc.
Jon Vance, Director, Avondale Partners, LLC
Related Insights
July 24, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
July 23, 2025
Foley Viewpoints
The One Big Beautiful Bill and Workplace Immigration Enforcement
The “One Big Beautiful Bill Act,” signed into law by President Trump on July 4, 2025, will fund government efforts to continue to…
July 23, 2025
Health Care Law Today
Update: CMS Extends Skilled Nursing Facilities’ Medicare Revalidation Deadline
On April 17, 2025, the Centers for Medicare and Medicaid Services (CMS) announced another extension of the deadline by which skilled nursing facilities (SNFs) must revalidate their Medicare enrollments.